The study is the largest to examine the impact of PSA screening trials and revised PSA screening guidelines on rates of prostate biopsy and the first to examine their impact on post-biopsy complications. The results, published in the March 2016 issue of European Urology, suggest a need to reduce the harm associated with biopsy.
"The recent guidelines urge that we are more thoughtful in our approach to PSA screening, and a downstream effect of that seems to be that we biopsy fewer patients, which has reduced the overall number of patients who experience biopsy-related complications," said R. Jeffrey Karnes, M.D., a urologist at Mayo Clinic in Rochester, Minnesota, and senior author of the study. "But we also found that the potential complications per patient went up, which means that we must continue to take steps to make biopsies as safe as possible."
This is one of many health care delivery findings made possible through the OptumLabs Data Warehouse. The goal of the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, which manages the OptumLabs relationship, is to enhance patient experience, while improving outcomes and cost.
Tags: About, Center for the Science of Health Care Delivery, Findings, Jeffrey Karnes, Kern Center, Mayo Clinic Cancer Center, Optum Labs, OptumLabs, prostate cancer, prostate cancer biopsy, prostate-specific antigen (PSA)